Professor Hector Chinoy, Michelle Beswick

Another UK 1st in myositis research

Congratulations to the Musculoskeletal Research Team who have recruited another first UK patient into a commercial study for myositis.

The Neptunia study is evaluating the efficacy and safety of enpatoran tablets twice daily for adults who’ve been diagnosed with dermatomyositis or polymyositis. The treatment is designed to potentially block specific cell pathways that may contribute to an overreac­tion of the immune system in people with myositis. The study is sponsored by Merck Healthcare KGaA.

Research Practitioner Michelle Beswick and Principal Investigator Professor Hector Chinoy recruited the first UK patient at the start of June, following their UK first on another commercial myositis study in March.

Prof Chinoy is also the lead researcher for the Idiopathic Inflammatory Myopathies (IIM), myositis collection within NCARC, our ethically approved biobank.

Skip to content